一種正在研制的新型冠脈支架用于治療分杈病變，已經(jīng)首次在臨床應(yīng)用。

Tryton側(cè)枝支架是由Tryton醫(yī)療公司(Newton, MA, USA)研制開發(fā)的，被設(shè)計用于治療冠狀動脈分杈病變。該支架使用獨(dú)特的氣囊擴(kuò)張，5個French兼容系統(tǒng)通過單一導(dǎo)線輸送。 當(dāng)與當(dāng)前使用的標(biāo)準(zhǔn)導(dǎo)管共同使用治療主要血管病變的時候，該系統(tǒng)能夠在側(cè)枝處提供效果更好覆蓋和環(huán)狀束縛力。Tryton側(cè)枝支架當(dāng)前僅用于研究目的。

在正在使用冠狀動脈支架的患者中，大約有25％發(fā)生位于側(cè)枝處的冠狀動脈疾病。但是，藥物釋放支架的設(shè)計并不能完全治療這些患者。放置在分杈處的支架目前會發(fā)生更多的急性并發(fā)癥和遠(yuǎn)期的再狹窄。
 
Stent Designed Specifically for Bifurcations
 
A new coronary stent being developed for the treatment of bifurcation lesions has been used clinically for the first time.

The Tryton side-branch stent, being developed by Tryton Medical (Newton, MA, USA), is designed to treat coronary artery arterial lesions involving a bifurcation. The stent is a unique balloon expandable, 5 French compatible system that is delivered with a single wire. When used in conjunction with any existing standard stent for the main vessel, it provides superior coverage and hoop strength to the origin of the side-branch. The Tryton side branch stent is currently for investigational use only.

Coronary artery disease located at the branch of arteries occurs in up to 25% of patients currently undergoing coronary stenting. However, the designs of available drug-eluting stents do not adequately address this group of patients. Stents placed at bifurcations are currently associated with higher acute complications as well as late restenosis.